Multikinase inhibitors in thyroid cancer: timing of targeted therapy

Nat Rev Endocrinol. 2021 Apr;17(4):225-234. doi: 10.1038/s41574-020-00465-y. Epub 2021 Feb 18.

Abstract

In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer with multikinase inhibitors, much has changed in the landscape of this heterogeneous disease. New multikinase and selective inhibitor treatments for medullary thyroid cancer, radioiodine-refractory thyroid cancer and anaplastic thyroid cancer have completed trials and improved progression-free survival. Many physicians are concerned by dose-limiting adverse effects of these drugs and are wary to begin treatment in patients who are systemically well but have marked disease burden, which makes the timing of treatment initiation challenging. Published mechanistic data on tyrosine kinase inhibitors (TKIs) have helped guide our understanding of how to dose effectively with these drugs. A major goal in TKI therapy is to optimize inhibition of oncogenic kinase drivers while maintaining patient quality of life. Real-world data have now been published on how TKIs have fared outside the clinical trial environment. In this Review, we provide a summary of published data on the efficacy of TKIs in clinical practice, to provide clinicians with a more realistic view of how their patients will manage and respond to TKI therapy. Furthermore, we review the data on mechanisms of inhibition, outcomes and adverse effects of TKIs and provide an update on targeted treatment of thyroid cancer, focusing on optimizing the timing of treatment initiation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anions
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Molecular Targeted Therapy / methods*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / enzymology
  • Treatment Outcome

Substances

  • Anions
  • Antineoplastic Agents
  • Protein Kinase Inhibitors